View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Pharmatest
24 November 2017

Pharmatest Credits Bruker for SkyScan 1276 in vivo micro-CT

After nine months’ experience, Pharmatest has given high credit to the performance of Bruker’s SkyScan 1276 High-Resolution and Fast In Vivo Desktop Micro-Computed Tomography (micro-CT), which was installed at its premises in February.

Bone biology expert Pharmatest Services has offered preclinical efficacy services in skeletal diseases since 1999. The firm has also been a pioneer in offering bone metastasis models since 2005.

The equipment has been very useful in Pharmatest in both skeletal disease and bone metastasis studies.

CEO of Pharmatest Jussi Halleen says: “We are very impressed about the excellent performance of the SkyScan 1276 in vivo micro-CT equipment, and the excellent training provided by Bruker for using the equipment. I would say that SkyScan 1276 is especially useful for bone specialists.”

Research director at Pharmatest Jukka Morko comments: “SkyScan 1276 gives the user many possibilities to modify and optimise scanning, reconstruction, and analysis settings for different kind of studies. This allows obtaining highest quality results, which is very important for Pharmatest in everything that we do.”

4T1 is a triple-negative mouse breast cancer cell line. Pharmatest utilises a 4T1 cell line with stable expression of green fluorescent protein (GFP) enabling easy...
Metastatic and primary tumours are known to respond differently to chemotherapy. Therefore, when establishing drug efficacy it is important not to rely only on experiments...
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology